$4.48
$251M
$183M
Pharmaceuticals
USD
Business Description (click to toggle)
| Key Statistics | |||||
|---|---|---|---|---|---|
| Valuation Ratios | 10-Yr Median Returns | 10-Yr Median Margins | |||
| P/E | 227.4 | ROA | -17.5% | Gross Profit | 51.8% |
| P/B | 0.6 | ROE | -23.2% | EBIT | -99.8% |
| P/S | 1.1 | ROIC | -18.8% | Pre-Tax Income | -115.1% |
| EV/S | 0.8 | 10-Year CAGR | FCF | -158.0% | |
| EV/EBITDA | 8.1 | Revenue | - | Capital Structure (Median) | |
| EV/EBIT | 26.4 | Assets | 61.0% | Assets / Equity | 1.4 |
| EV/Pretax | 12.9 | FCF | - | Debt / Equity | 0.2 |
| EV/FCF | -321.4 | EPS | - | Debt / Assets | 0.2 |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | |
| Revenue | - | 1 | 14 | 42 | 185 | 198 | 201 | 173 | 199 | 239 |
| Revenue Growth | - | - | 1,117.7% | 209.5% | 339.4% | 7.3% | 1.2% | -13.9% | 15.2% | 20.0% |
| Gross Profit | - | 2 | 12 | 33 | 107 | -15 | -18 | 17 | 97 | 131 |
| Gross Margin % | - | 153.0% | 88.9% | 78.8% | 58.0% | -7.4% | -8.8% | 9.6% | 48.9% | 54.6% |
| Operating Profit | -8 | -4 | -7 | -61 | -227 | -341 | -202 | -171 | -23 | 7 |
| Operating Margin % | - | -319.0% | -53.4% | -145.1% | -122.6% | -171.8% | -100.6% | -99.1% | -11.5% | 2.9% |
| Earnings Per Share | $-11.65 | $-3.72 | $-4.51 | $13.71 | $-27.54 | $-250.37 | $-33.55 | $-62.40 | $-1.12 | $0.03 |
| EPS Growth | 4.4% | 68.0% | -21.2% | 403.9% | -300.8% | -809.0% | 86.6% | -86.0% | 98.2% | 102.5% |
| Return on Assets | -96.2% | -35.2% | -7.6% | 6.5% | -7.9% | -78.3% | -27.1% | -90.1% | -7.0% | 0.2% |
| Return on Equity | -325.3% | -114.9% | -11.5% | 8.2% | -9.9% | -99.2% | -34.9% | -122.8% | -11.0% | 0.3% |
| Return on Invested Capital | -116.6% | -39.2% | -8.7% | 7.1% | -8.6% | -84.6% | -28.9% | -98.9% | -8.0% | 0.2% |